Collegium Pharmaceutical, Inc. (COLL) fair value analysis
Nasdaq · Updated 2026-10-19
COLL price how computed
Forward Fair Value verdict
UndervaluedCOLL is trading at more than a 25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $23.19
- Sector
- Healthcare
- 12-month range
- $21.53–$49.84
- Market cap
- $755M
- From 52-week high
- -53.5%
- Shares outstanding
- 32.6M
- Rank in Healthcare by discount to fair value
- #6 of 108
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company that develops and commercializes pain management and addiction treatment medications. The company operates primarily in the United States healthcare market.
COLL currently ranks #6 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 14 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $755M
- P/E (trailing)
- 3x
- Revenue (TTM)
- $808M
- Net margin
- 5.9%
- EPS (TTM)
- $7.43
- Gross margin
- 55.2%
- Debt / equity
- 2.75
- Revenue growth (3-yr avg)
- 15.4%
- Shares outstanding
- 32.6M
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Expanding
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 62 · neutral
- 50-day average
- $24.19
- 200-day average
- $34.41
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-11-05
- Last 8 quarters vs consensus
- 7 beat, 1 missed
- Quarter by quarter
- 2026-06 ▲ beat (+6.1%)
2026-03 ▲ beat (+15.8%)
2025-12 ▼ miss (-8.0%)
2025-09 ▲ beat (+21.0%)
2025-06 ▲ beat (+2.8%)
2025-03 ▲ beat (+2.8%)
2024-12 ▲ beat (+15.1%)
2024-09 ▲ beat (+1.3%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 7 buy · 1 hold · 0 sell (8 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $49
- Target vs last price
- +111.3%
What our data shows for COLL
- Our model validated 12 trailing price-to-earnings windows for COLL, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $21.53–$49.84.
- The 14-day relative strength index sits at a neutral 62.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for COLL
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent COLL news
TickrTrends' derived news-sentiment signal for COLL is currently mixed, computed from recent coverage.
- Collegium Pharmaceutical (COLL) Settles Patent Dispute with Grünenthal, Ending Royalty Obligations (gurufocus.com, 2026-10-19)
TickrTrends take: The settlement of Collegium Pharmaceutical's patent dispute with Grünenthal eliminates future royalty obligations, which should improve the company's cash flow profile going forward. TickrTrends currently rates COLL as undervalued, and resolution of this legal uncertainty removes a contingent liability that previously weighed on the company's financial trajectory. Investors monitoring the Healthcare sector should track whether this obligation elimination translates into expanded margins or accelerated profitability in upcoming quarters. - Collegium Pharmaceutical: Under 3x Cash Earnings After A Narrow Guidance Cut (NASDAQ:COLL) (seekingalpha.com, 2026-10-17)
TickrTrends take: Collegium Pharmaceutical trades at a multiple below 3 times its cash earnings, a metric that TickrTrends currently identifies as undervalued for this Healthcare sector company. The recent guidance reduction suggests investors should monitor whether the company can maintain its cash generation capability going forward, as earnings quality becomes more important at lower valuation multiples. Readers focused on valuation should track whether management's revised outlook stabilizes or indicates deeper operational challenges that could pressure the cash earnings multiple higher. - COLL Initiates Coverage On Collegium Pharmaceutical -- Outperform Rating by Oppenheimer (gurufocus.com, 2026-09-23)
TickrTrends take: Oppenheimer's initiation of coverage with an Outperform rating on Collegium Pharmaceutical aligns with TickrTrends' current assessment that the stock trades at an undervalued level within the Healthcare sector. The analyst endorsement of the company's prospects could support the thesis that the market has not fully reflected the company's potential, particularly relevant for investors focused on valuation metrics. A valuation-focused reader should monitor whether this analyst attention contributes to multiple expansion or whether fundamental metrics continue to suggest the stock remains discounted relative to comparable Healthcare companies.
More COLL news
- Collegium Pharmaceutical, Inc. (COLL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript (seekingalpha.com, 2026-09-16)
- COLL Maintained by Truist Securities -- Price Target Lowered to $49 (gurufocus.com, 2026-09-09)
What people are saying
Follow the COLL conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for COLL showed a shift in the Relative Strength Index zone this week, moving from oversold to neutral territory. The stock currently maintains an undervalued valuation verdict within the Healthcare sector. This change suggests the stock's momentum has moved away from the oversold conditions observed in the prior week.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-21 — TickrTrends' derived indicators for COLL show a shift in momentum this week, with the Relative Strength Index moving from neutral territory into oversold zone. The stock remains classified as undervalued based on current valuation metrics. This combination of oversold momentum conditions with an undervalued classification may indicate potential interest from value-oriented investors.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is COLL stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), COLL is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is COLL's TickrTrends verdict?
COLL's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does COLL compare to other Healthcare stocks?
COLL ranks #6 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is COLL overbought or oversold?
COLL's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does COLL report earnings next?
COLL's next earnings report is scheduled for 2026-11-05, per the published earnings calendar.
Does COLL usually beat earnings estimates?
Over its last 8 reported quarters COLL beat the consensus estimate 7 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about COLL?
Of 8 analysts covering COLL, 7 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $49 (+111.3% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
COLL vs ADMA · COLL vs ALGN · COLL vs ANIP · COLL vs ASTH · COLL vs AZN